XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
The software enables real-time communication between patients, caregivers, physicians, and pharmacists and each cartridge in the device has a unique, traceable serial number registered to the patient
This brings hope for patients suffering from all types of hernia, as the centre has a replenished armamentarium of technology and techniques to produce a good outcome
The Endosonography allows the use of EUS guided Fine needle aspiration for accurate diagnosis of GI cancers without the need for conventional biopsies
It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)
New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
The company's discovery services support a wide range of global innovator companies from start-ups to large pharma companies, across a diverse set of therapeutic areas including oncology, CNS, antivirals, and inflammation among others
It is estimated that 300 million men worldwide were affected by ED in 2020, a figure projected to increase to 322 million by 2025. Nearly 30% of these were aged between 40 and 70
It measures 9 French (3 millimetres) in diameter upon insertion and removal from the body. While in the heart, it expands to support the heart’s pumping function, providing flow greater than 3.5 L/min
Subscribe To Our Newsletter & Stay Updated
